Issue Brief

This paper raises several important questions about the current location, funding and process of approving the Obama Presidential Center on Chicago's South Side.

Senate filibuster repeal or reform is being considered once again. Returning to the “talking filibuster” wouldn’t change the 60 votes needed to end debate, but it could expedite the process.

Today, the United States is on the verge of achieving not just energy independence, but energy dominance—but not because of taxpayer-provided subsidies to alternative and renewable energies. Rather, new drilling innovations and technologies have made the U.S. the world’s largest producer of crude oil and natural gas.

President Trump and many in Congress want to reduce prescription drug prices. This paper discusses how drug prices are determined and explains why political efforts to reduce them would be both harmful and counterproductive. 

Let consumers buy the kind of insurance coverage they want, not what politicians think they should have, and give insurers the freedom to offer those policies.

The Medicare Part B prescription drug program works reasonably well, providing some of the sickest patients with access to the newest and most innovative drugs. Now MedPAC wants to change it, and not for the better.

Calls for more "price transparency" have tended to be selective. But access to prices is a problem throughout the health care system, and many "solutions" do nothing but exacerbate the problem.

This paper suggests several new policies designed to create a reasonable, secure, functioning immigration system that is in the best interests of the United States. It further suggests a specific approach to dealing humanely and realistically with the current illegal population.

A gene trait in the first of the biotech seeds, Roundup Ready, goes off patent in 2014, and many more will soon follow. The industry has been developing a private sector process to govern the transition from patented to generic traits that relies on negotiations and contracts. Such a process would avoid the costly, litigious and adversarial approach Congress imposed on the pharmaceutical industry.